Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C
Related Experiment Video
Updated: Jun 3, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Ali A Weinstein1, Jillian Kallman Price, Maria Stepanova
1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.
Insights
Depression is common in non-alcoholic fatty liver disease (NAFLD) and Hepatitis C (HCV) patients, but less so in Hepatitis B (HBV) patients. Female gender and alcohol use are key predictors of depression in chronic liver disease.
Area of Science:
- Hepatology
- Psychiatry
- Epidemiology
Background:
- Chronic liver disease (CLD) patients face increased risks, including poor quality of life and disease progression, when experiencing depression.
- Understanding depression prevalence and its correlates in CLD is crucial for patient management.
Purpose of the Study:
- To determine the prevalence of depression in patients with non-alcoholic fatty liver disease (NAFLD), Hepatitis B (HBV), and Hepatitis C (HCV).
- To identify clinical and laboratory factors associated with depression in these CLD patient groups.
Main Methods:
- Utilized a CLD patient database with comprehensive clinical and laboratory data.
- Compared depression prevalence across NAFLD, HBV, and HCV patient cohorts.
- Employed regression models to identify independent predictors of depression.
Main Results:
- 23.6% of 878 CLD patients had depression: NAFLD (27.2%), HCV (29.8%), HBV (3.7%).
- Predictors varied by CLD type: NAFLD (hypertension, smoking, female, non-African-American), HBV (excessive alcohol), HCV (female, non-Asian, fatigue, excessive alcohol).
Conclusions:
- NAFLD and HCV patients exhibit higher depression rates than HBV patients and the general population.
- Female gender and excessive alcohol consumption are consistent correlates of depression in CLD patients.
Background:
Patients with chronic liver disease (CLD) and depression may be at a higher risk for various complications, including impaired quality of life and more advanced liver disease. The purpose of this study was to determine the prevalence of depression in CLD patients (non-alcoholic fatty liver disease (NAFLD), Hepatitis B (HBV), and Hepatitis C (HCV)) and to identify potential clinical and laboratory correlates of depression in these patients.
Methods:
We used a database of CLD patients that contains extensive clinical (including self-reported depression) and laboratory data for each patient. We compared the prevalence of depression in patients with HBV, HCV, and NAFLD. We also used regression models to find independent predictors of depression in these patients.
Results:
Of 878 CLD patients, 207 (23.6%) had a diagnosis of depression (NAFLD 27.2%, HCV 29.8%, and HBV 3.7%). Examination of predictors of depression differed by the type of chronic liver disease. For NAFLD, independent predictors of depression were the presence of hypertension, smoking, history of lung disease, being female, and non-African-American. For HBV patients, the only independent predictor of depression was excessive alcohol consumption (defined as >10 g/d), while for HCV patients, independent predictors were being female and non-Asian, presence of fatigue, and excessive alcohol intake.
Conclusions:
This study demonstrates that individuals with NAFLD and HCV have a higher prevalence of depression than HBV patients and the rates of depression reported for the general population. The most consistent correlates of depression status in CLD patients are being female and excessive alcohol consumption.
Related Concept Videos
Hepatitis
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Viral Hepatitis I: Introduction
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

